Inhibikase Therapeutics IKT
NASDAQ IKT
$2.00 +0.07 (+3.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026)

Updated

Inhibikase Therapeutics' Change in Accured Expenses was $5.14 million in Q2 2026, compared with -$575,063 a year earlier.

Analysis

Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, Inhibikase Therapeutics' Change in Accured Expenses was $6.33 million through Jun 30, 2026, up 600.5% year-over-year; for FY2025, it was $1.4 million, up 233.6% from FY2024.

  • In earlier years, Change in Accured Expenses was $420,075 in FY2024, -$138,481 in FY2023, -$317,324 in FY2022 and $2.08 million in FY2021.
  • The Q2 2026 figure marks the highest quarterly Change in Accured Expenses in data going back to Q1 2020.
  • Compared with a year earlier, Change in Accured Expenses was higher in four of the last six quarters, with growth averaging 164.0%.
  • The best year-over-year quarter for Change in Accured Expenses over five years was Q4 2021 (growth of 755.7%); the worst was Q1 2026 (a decline of 94.8%).
  • Per Business Quant data, IKT's Change in Accured Expenses in the three quarters before Q2 2026 was $43,372 (Q1 2026), $424,899 (Q4 2025) and $718,197 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 2.96 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 1.20 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -251.00 Mn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 901.00 Mn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 338.00 Mn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Inhibikase Therapeutics 349.14 Mn -236.33 Mn - 5.14 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.14 Mn
Mar 31, 2026 43,372.00
Dec 31, 2025 424,899.00
Sep 30, 2025 718,197.00
Jun 30, 2025 -575,063.00
Mar 31, 2025 833,219.00
Dec 31, 2024 518,656.00
Sep 30, 2024 126,849.00
Jun 30, 2024 -473,064.00
Mar 31, 2024 247,634.00
Dec 31, 2023 401,740.00
Sep 30, 2023 27,288.00
Jun 30, 2023 272,706.00
Mar 31, 2023 -840,215.00
Dec 31, 2022 132,394.00
Sep 30, 2022 -1.34 Mn
Jun 30, 2022 32,176.00
Mar 31, 2022 858,240.00
Dec 31, 2021 810,751.00
Sep 30, 2021 1.03 Mn
API Access

Inhibikase Therapeutics Change in Accured Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEY